 | • レポートコード：QFJ1-5587 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、108ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査レポートでは、抗パーキンソン薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（ドーパミン作動薬、ドーパミン作動薬、酵素阻害薬、その他）、用途別市場規模（病院薬局、小売薬局、オンラインストア）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・抗パーキンソン薬の市場動向 ・企業の競争状況、市場シェア ・抗パーキンソン薬の種類別市場規模と予測2016-2027（ドーパミン作動薬、ドーパミン作動薬、酵素阻害薬、その他） ・抗パーキンソン薬の用途別市場規模と予測2016-2027（病院薬局、小売薬局、オンラインストア） ・抗パーキンソン薬の北米市場規模2016-2027（アメリカ、カナダ） ・抗パーキンソン薬の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・抗パーキンソン薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・抗パーキンソン薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・抗パーキンソン薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（AbbVie、Mylan Laboratories、Valeant Pharmaceuticals、Novartis、GlaxoSmithKline、Zambon Pharmaceuticals、Pfizer, Inc.、Hoffmann-La Roche、Merck & Co.、Orion Pharma、UCB、Teva Pharmaceutical Industries Ltd.、Vertical Pharmaceuticals, LLC、ACADIA Pharmaceuticals Inc.） ・結論 |
Anti-Parkinson Drugs are drugs used to treat Parkinson’s disease.
The most commonly used Anti-Parkinson Drugs act on the dopaminergic system of the striatum and basal ganglia, or are central muscarinic antagonists.
Market Analysis and Insights: Global Anti-Parkinson Drugs Market
The global Anti-Parkinson Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Anti-Parkinson Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Anti-Parkinson Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Anti-Parkinson Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Anti-Parkinson Drugs market.
Global Anti-Parkinson Drugs Scope and Market Size
Anti-Parkinson Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Anti-Parkinson Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Dopaminergic
Dopamine Agonists
Enzyme Inhibitors
Others
Segment by Application
Hospital Pharmacy
Retail Pharmacy
Online Stores
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
AbbVie
Mylan Laboratories
Valeant Pharmaceuticals
Novartis
GlaxoSmithKline
Zambon Pharmaceuticals
Pfizer, Inc.
Hoffmann-La Roche
Merck & Co.
Orion Pharma
UCB
Teva Pharmaceutical Industries Ltd.
Vertical Pharmaceuticals, LLC
ACADIA Pharmaceuticals Inc.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Anti-Parkinson Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Dopaminergic
1.2.3 Dopamine Agonists
1.2.4 Enzyme Inhibitors
1.2.5 Others
1.3 Market by Application
1.3.1 Global Anti-Parkinson Drugs Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Stores
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Anti-Parkinson Drugs Market Perspective (2016-2027)
2.2 Anti-Parkinson Drugs Growth Trends by Regions
2.2.1 Anti-Parkinson Drugs Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Anti-Parkinson Drugs Historic Market Share by Regions (2016-2021)
2.2.3 Anti-Parkinson Drugs Forecasted Market Size by Regions (2022-2027)
2.3 Anti-Parkinson Drugs Industry Dynamic
2.3.1 Anti-Parkinson Drugs Market Trends
2.3.2 Anti-Parkinson Drugs Market Drivers
2.3.3 Anti-Parkinson Drugs Market Challenges
2.3.4 Anti-Parkinson Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Anti-Parkinson Drugs Players by Revenue
3.1.1 Global Top Anti-Parkinson Drugs Players by Revenue (2016-2021)
3.1.2 Global Anti-Parkinson Drugs Revenue Market Share by Players (2016-2021)
3.2 Global Anti-Parkinson Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Anti-Parkinson Drugs Revenue
3.4 Global Anti-Parkinson Drugs Market Concentration Ratio
3.4.1 Global Anti-Parkinson Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Anti-Parkinson Drugs Revenue in 2020
3.5 Anti-Parkinson Drugs Key Players Head office and Area Served
3.6 Key Players Anti-Parkinson Drugs Product Solution and Service
3.7 Date of Enter into Anti-Parkinson Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Anti-Parkinson Drugs Breakdown Data by Type
4.1 Global Anti-Parkinson Drugs Historic Market Size by Type (2016-2021)
4.2 Global Anti-Parkinson Drugs Forecasted Market Size by Type (2022-2027)
5 Anti-Parkinson Drugs Breakdown Data by Application
5.1 Global Anti-Parkinson Drugs Historic Market Size by Application (2016-2021)
5.2 Global Anti-Parkinson Drugs Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Anti-Parkinson Drugs Market Size (2016-2027)
6.2 North America Anti-Parkinson Drugs Market Size by Type
6.2.1 North America Anti-Parkinson Drugs Market Size by Type (2016-2021)
6.2.2 North America Anti-Parkinson Drugs Market Size by Type (2022-2027)
6.2.3 North America Anti-Parkinson Drugs Market Size by Type (2016-2027)
6.3 North America Anti-Parkinson Drugs Market Size by Application
6.3.1 North America Anti-Parkinson Drugs Market Size by Application (2016-2021)
6.3.2 North America Anti-Parkinson Drugs Market Size by Application (2022-2027)
6.3.3 North America Anti-Parkinson Drugs Market Size by Application (2016-2027)
6.4 North America Anti-Parkinson Drugs Market Size by Country
6.4.1 North America Anti-Parkinson Drugs Market Size by Country (2016-2021)
6.4.2 North America Anti-Parkinson Drugs Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Anti-Parkinson Drugs Market Size (2016-2027)
7.2 Europe Anti-Parkinson Drugs Market Size by Type
7.2.1 Europe Anti-Parkinson Drugs Market Size by Type (2016-2021)
7.2.2 Europe Anti-Parkinson Drugs Market Size by Type (2022-2027)
7.2.3 Europe Anti-Parkinson Drugs Market Size by Type (2016-2027)
7.3 Europe Anti-Parkinson Drugs Market Size by Application
7.3.1 Europe Anti-Parkinson Drugs Market Size by Application (2016-2021)
7.3.2 Europe Anti-Parkinson Drugs Market Size by Application (2022-2027)
7.3.3 Europe Anti-Parkinson Drugs Market Size by Application (2016-2027)
7.4 Europe Anti-Parkinson Drugs Market Size by Country
7.4.1 Europe Anti-Parkinson Drugs Market Size by Country (2016-2021)
7.4.2 Europe Anti-Parkinson Drugs Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Anti-Parkinson Drugs Market Size (2016-2027)
8.2 Asia-Pacific Anti-Parkinson Drugs Market Size by Type
8.2.1 Asia-Pacific Anti-Parkinson Drugs Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Anti-Parkinson Drugs Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Anti-Parkinson Drugs Market Size by Type (2016-2027)
8.3 Asia-Pacific Anti-Parkinson Drugs Market Size by Application
8.3.1 Asia-Pacific Anti-Parkinson Drugs Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Anti-Parkinson Drugs Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Anti-Parkinson Drugs Market Size by Application (2016-2027)
8.4 Asia-Pacific Anti-Parkinson Drugs Market Size by Region
8.4.1 Asia-Pacific Anti-Parkinson Drugs Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Anti-Parkinson Drugs Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Anti-Parkinson Drugs Market Size (2016-2027)
9.2 Latin America Anti-Parkinson Drugs Market Size by Type
9.2.1 Latin America Anti-Parkinson Drugs Market Size by Type (2016-2021)
9.2.2 Latin America Anti-Parkinson Drugs Market Size by Type (2022-2027)
9.2.3 Latin America Anti-Parkinson Drugs Market Size by Type (2016-2027)
9.3 Latin America Anti-Parkinson Drugs Market Size by Application
9.3.1 Latin America Anti-Parkinson Drugs Market Size by Application (2016-2021)
9.3.2 Latin America Anti-Parkinson Drugs Market Size by Application (2022-2027)
9.3.3 Latin America Anti-Parkinson Drugs Market Size by Application (2016-2027)
9.4 Latin America Anti-Parkinson Drugs Market Size by Country
9.4.1 Latin America Anti-Parkinson Drugs Market Size by Country (2016-2021)
9.4.2 Latin America Anti-Parkinson Drugs Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Anti-Parkinson Drugs Market Size (2016-2027)
10.2 Middle East & Africa Anti-Parkinson Drugs Market Size by Type
10.2.1 Middle East & Africa Anti-Parkinson Drugs Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Anti-Parkinson Drugs Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Anti-Parkinson Drugs Market Size by Type (2016-2027)
10.3 Middle East & Africa Anti-Parkinson Drugs Market Size by Application
10.3.1 Middle East & Africa Anti-Parkinson Drugs Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Anti-Parkinson Drugs Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Anti-Parkinson Drugs Market Size by Application (2016-2027)
10.4 Middle East & Africa Anti-Parkinson Drugs Market Size by Country
10.4.1 Middle East & Africa Anti-Parkinson Drugs Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Anti-Parkinson Drugs Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 AbbVie
11.1.1 AbbVie Company Details
11.1.2 AbbVie Business Overview
11.1.3 AbbVie Anti-Parkinson Drugs Introduction
11.1.4 AbbVie Revenue in Anti-Parkinson Drugs Business (2016-2021)
11.1.5 AbbVie Recent Development
11.2 Mylan Laboratories
11.2.1 Mylan Laboratories Company Details
11.2.2 Mylan Laboratories Business Overview
11.2.3 Mylan Laboratories Anti-Parkinson Drugs Introduction
11.2.4 Mylan Laboratories Revenue in Anti-Parkinson Drugs Business (2016-2021)
11.2.5 Mylan Laboratories Recent Development
11.3 Valeant Pharmaceuticals
11.3.1 Valeant Pharmaceuticals Company Details
11.3.2 Valeant Pharmaceuticals Business Overview
11.3.3 Valeant Pharmaceuticals Anti-Parkinson Drugs Introduction
11.3.4 Valeant Pharmaceuticals Revenue in Anti-Parkinson Drugs Business (2016-2021)
11.3.5 Valeant Pharmaceuticals Recent Development
11.4 Novartis
11.4.1 Novartis Company Details
11.4.2 Novartis Business Overview
11.4.3 Novartis Anti-Parkinson Drugs Introduction
11.4.4 Novartis Revenue in Anti-Parkinson Drugs Business (2016-2021)
11.4.5 Novartis Recent Development
11.5 GlaxoSmithKline
11.5.1 GlaxoSmithKline Company Details
11.5.2 GlaxoSmithKline Business Overview
11.5.3 GlaxoSmithKline Anti-Parkinson Drugs Introduction
11.5.4 GlaxoSmithKline Revenue in Anti-Parkinson Drugs Business (2016-2021)
11.5.5 GlaxoSmithKline Recent Development
11.6 Zambon Pharmaceuticals
11.6.1 Zambon Pharmaceuticals Company Details
11.6.2 Zambon Pharmaceuticals Business Overview
11.6.3 Zambon Pharmaceuticals Anti-Parkinson Drugs Introduction
11.6.4 Zambon Pharmaceuticals Revenue in Anti-Parkinson Drugs Business (2016-2021)
11.6.5 Zambon Pharmaceuticals Recent Development
11.7 Pfizer, Inc.
11.7.1 Pfizer, Inc. Company Details
11.7.2 Pfizer, Inc. Business Overview
11.7.3 Pfizer, Inc. Anti-Parkinson Drugs Introduction
11.7.4 Pfizer, Inc. Revenue in Anti-Parkinson Drugs Business (2016-2021)
11.7.5 Pfizer, Inc. Recent Development
11.8 Hoffmann-La Roche
11.8.1 Hoffmann-La Roche Company Details
11.8.2 Hoffmann-La Roche Business Overview
11.8.3 Hoffmann-La Roche Anti-Parkinson Drugs Introduction
11.8.4 Hoffmann-La Roche Revenue in Anti-Parkinson Drugs Business (2016-2021)
11.8.5 Hoffmann-La Roche Recent Development
11.9 Merck & Co.
11.9.1 Merck & Co. Company Details
11.9.2 Merck & Co. Business Overview
11.9.3 Merck & Co. Anti-Parkinson Drugs Introduction
11.9.4 Merck & Co. Revenue in Anti-Parkinson Drugs Business (2016-2021)
11.9.5 Merck & Co. Recent Development
11.10 Orion Pharma
11.10.1 Orion Pharma Company Details
11.10.2 Orion Pharma Business Overview
11.10.3 Orion Pharma Anti-Parkinson Drugs Introduction
11.10.4 Orion Pharma Revenue in Anti-Parkinson Drugs Business (2016-2021)
11.10.5 Orion Pharma Recent Development
11.11 UCB
11.11.1 UCB Company Details
11.11.2 UCB Business Overview
11.11.3 UCB Anti-Parkinson Drugs Introduction
11.11.4 UCB Revenue in Anti-Parkinson Drugs Business (2016-2021)
11.11.5 UCB Recent Development
11.12 Teva Pharmaceutical Industries Ltd.
11.12.1 Teva Pharmaceutical Industries Ltd. Company Details
11.12.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.12.3 Teva Pharmaceutical Industries Ltd. Anti-Parkinson Drugs Introduction
11.12.4 Teva Pharmaceutical Industries Ltd. Revenue in Anti-Parkinson Drugs Business (2016-2021)
11.12.5 Teva Pharmaceutical Industries Ltd. Recent Development
11.13 Vertical Pharmaceuticals, LLC
11.13.1 Vertical Pharmaceuticals, LLC Company Details
11.13.2 Vertical Pharmaceuticals, LLC Business Overview
11.13.3 Vertical Pharmaceuticals, LLC Anti-Parkinson Drugs Introduction
11.13.4 Vertical Pharmaceuticals, LLC Revenue in Anti-Parkinson Drugs Business (2016-2021)
11.13.5 Vertical Pharmaceuticals, LLC Recent Development
11.14 ACADIA Pharmaceuticals Inc.
11.14.1 ACADIA Pharmaceuticals Inc. Company Details
11.14.2 ACADIA Pharmaceuticals Inc. Business Overview
11.14.3 ACADIA Pharmaceuticals Inc. Anti-Parkinson Drugs Introduction
11.14.4 ACADIA Pharmaceuticals Inc. Revenue in Anti-Parkinson Drugs Business (2016-2021)
11.14.5 ACADIA Pharmaceuticals Inc. Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Anti-Parkinson Drugs Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Dopaminergic
Table 3. Key Players of Dopamine Agonists
Table 4. Key Players of Enzyme Inhibitors
Table 5. Key Players of Others
Table 6. Global Anti-Parkinson Drugs Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Anti-Parkinson Drugs Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Anti-Parkinson Drugs Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Anti-Parkinson Drugs Market Share by Regions (2016-2021)
Table 10. Global Anti-Parkinson Drugs Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Anti-Parkinson Drugs Market Share by Regions (2022-2027)
Table 12. Anti-Parkinson Drugs Market Trends
Table 13. Anti-Parkinson Drugs Market Drivers
Table 14. Anti-Parkinson Drugs Market Challenges
Table 15. Anti-Parkinson Drugs Market Restraints
Table 16. Global Anti-Parkinson Drugs Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Anti-Parkinson Drugs Market Share by Players (2016-2021)
Table 18. Global Top Anti-Parkinson Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Anti-Parkinson Drugs as of 2020)
Table 19. Ranking of Global Top Anti-Parkinson Drugs Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Anti-Parkinson Drugs Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Anti-Parkinson Drugs Product Solution and Service
Table 23. Date of Enter into Anti-Parkinson Drugs Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Anti-Parkinson Drugs Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Anti-Parkinson Drugs Revenue Market Share by Type (2016-2021)
Table 27. Global Anti-Parkinson Drugs Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Anti-Parkinson Drugs Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Anti-Parkinson Drugs Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Anti-Parkinson Drugs Revenue Market Share by Application (2016-2021)
Table 31. Global Anti-Parkinson Drugs Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Anti-Parkinson Drugs Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Anti-Parkinson Drugs Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Anti-Parkinson Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Anti-Parkinson Drugs Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Anti-Parkinson Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Anti-Parkinson Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Anti-Parkinson Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Anti-Parkinson Drugs Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Anti-Parkinson Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Anti-Parkinson Drugs Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Anti-Parkinson Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Anti-Parkinson Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Anti-Parkinson Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Anti-Parkinson Drugs Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Anti-Parkinson Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Anti-Parkinson Drugs Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Anti-Parkinson Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Anti-Parkinson Drugs Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Anti-Parkinson Drugs Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Anti-Parkinson Drugs Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Anti-Parkinson Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Anti-Parkinson Drugs Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Anti-Parkinson Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Anti-Parkinson Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Anti-Parkinson Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Anti-Parkinson Drugs Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Anti-Parkinson Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Anti-Parkinson Drugs Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Anti-Parkinson Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Anti-Parkinson Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Anti-Parkinson Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 63. AbbVie Company Details
Table 64. AbbVie Business Overview
Table 65. AbbVie Anti-Parkinson Drugs Product
Table 66. AbbVie Revenue in Anti-Parkinson Drugs Business (2016-2021) & (US$ Million)
Table 67. AbbVie Recent Development
Table 68. Mylan Laboratories Company Details
Table 69. Mylan Laboratories Business Overview
Table 70. Mylan Laboratories Anti-Parkinson Drugs Product
Table 71. Mylan Laboratories Revenue in Anti-Parkinson Drugs Business (2016-2021) & (US$ Million)
Table 72. Mylan Laboratories Recent Development
Table 73. Valeant Pharmaceuticals Company Details
Table 74. Valeant Pharmaceuticals Business Overview
Table 75. Valeant Pharmaceuticals Anti-Parkinson Drugs Product
Table 76. Valeant Pharmaceuticals Revenue in Anti-Parkinson Drugs Business (2016-2021) & (US$ Million)
Table 77. Valeant Pharmaceuticals Recent Development
Table 78. Novartis Company Details
Table 79. Novartis Business Overview
Table 80. Novartis Anti-Parkinson Drugs Product
Table 81. Novartis Revenue in Anti-Parkinson Drugs Business (2016-2021) & (US$ Million)
Table 82. Novartis Recent Development
Table 83. GlaxoSmithKline Company Details
Table 84. GlaxoSmithKline Business Overview
Table 85. GlaxoSmithKline Anti-Parkinson Drugs Product
Table 86. GlaxoSmithKline Revenue in Anti-Parkinson Drugs Business (2016-2021) & (US$ Million)
Table 87. GlaxoSmithKline Recent Development
Table 88. Zambon Pharmaceuticals Company Details
Table 89. Zambon Pharmaceuticals Business Overview
Table 90. Zambon Pharmaceuticals Anti-Parkinson Drugs Product
Table 91. Zambon Pharmaceuticals Revenue in Anti-Parkinson Drugs Business (2016-2021) & (US$ Million)
Table 92. Zambon Pharmaceuticals Recent Development
Table 93. Pfizer, Inc. Company Details
Table 94. Pfizer, Inc. Business Overview
Table 95. Pfizer, Inc. Anti-Parkinson Drugs Product
Table 96. Pfizer, Inc. Revenue in Anti-Parkinson Drugs Business (2016-2021) & (US$ Million)
Table 97. Pfizer, Inc. Recent Development
Table 98. Hoffmann-La Roche Company Details
Table 99. Hoffmann-La Roche Business Overview
Table 100. Hoffmann-La Roche Revenue in Anti-Parkinson Drugs Business (2016-2021) & (US$ Million)
Table 101. Hoffmann-La Roche Recent Development
Table 102. Merck & Co. Company Details
Table 103. Merck & Co. Business Overview
Table 104. Merck & Co. Anti-Parkinson Drugs Product
Table 105. Merck & Co. Revenue in Anti-Parkinson Drugs Business (2016-2021) & (US$ Million)
Table 106. Merck & Co. Recent Development
Table 107. Orion Pharma Company Details
Table 108. Orion Pharma Business Overview
Table 109. Orion Pharma Anti-Parkinson Drugs Product
Table 110. Orion Pharma Revenue in Anti-Parkinson Drugs Business (2016-2021) & (US$ Million)
Table 111. Orion Pharma Recent Development
Table 112. UCB Company Details
Table 113. UCB Business Overview
Table 114. UCB Anti-Parkinson Drugs Product
Table 115. UCB Revenue in Anti-Parkinson Drugs Business (2016-2021) & (US$ Million)
Table 116. UCB Recent Development
Table 117. Teva Pharmaceutical Industries Ltd. Company Details
Table 118. Teva Pharmaceutical Industries Ltd. Business Overview
Table 119. Teva Pharmaceutical Industries Ltd. Anti-Parkinson Drugs Product
Table 120. Teva Pharmaceutical Industries Ltd. Revenue in Anti-Parkinson Drugs Business (2016-2021) & (US$ Million)
Table 121. Teva Pharmaceutical Industries Ltd. Recent Development
Table 122. Vertical Pharmaceuticals, LLC Company Details
Table 123. Vertical Pharmaceuticals, LLC Business Overview
Table 124. Vertical Pharmaceuticals, LLC Anti-Parkinson Drugs Product
Table 125. Vertical Pharmaceuticals, LLC Revenue in Anti-Parkinson Drugs Business (2016-2021) & (US$ Million)
Table 126. Vertical Pharmaceuticals, LLC Recent Development
Table 127. ACADIA Pharmaceuticals Inc. Company Details
Table 128. ACADIA Pharmaceuticals Inc. Business Overview
Table 129. ACADIA Pharmaceuticals Inc. Anti-Parkinson Drugs Product
Table 130. ACADIA Pharmaceuticals Inc. Revenue in Anti-Parkinson Drugs Business (2016-2021) & (US$ Million)
Table 131. ACADIA Pharmaceuticals Inc. Recent Development
Table 132. Research Programs/Design for This Report
Table 133. Key Data Information from Secondary Sources
Table 134. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Anti-Parkinson Drugs Market Share by Type: 2020 VS 2027
Figure 2. Dopaminergic Features
Figure 3. Dopamine Agonists Features
Figure 4. Enzyme Inhibitors Features
Figure 5. Others Features
Figure 6. Global Anti-Parkinson Drugs Market Share by Application: 2020 VS 2027
Figure 7. Hospital Pharmacy Case Studies
Figure 8. Retail Pharmacy Case Studies
Figure 9. Online Stores Case Studies
Figure 10. Anti-Parkinson Drugs Report Years Considered
Figure 11. Global Anti-Parkinson Drugs Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global Anti-Parkinson Drugs Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Anti-Parkinson Drugs Market Share by Regions: 2020 VS 2027
Figure 14. Global Anti-Parkinson Drugs Market Share by Regions (2022-2027)
Figure 15. Global Anti-Parkinson Drugs Market Share by Players in 2020
Figure 16. Global Top Anti-Parkinson Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Anti-Parkinson Drugs as of 2020
Figure 17. The Top 10 and 5 Players Market Share by Anti-Parkinson Drugs Revenue in 2020
Figure 18. Global Anti-Parkinson Drugs Revenue Market Share by Type (2016-2021)
Figure 19. Global Anti-Parkinson Drugs Revenue Market Share by Type (2022-2027)
Figure 20. North America Anti-Parkinson Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America Anti-Parkinson Drugs Market Share by Type (2016-2027)
Figure 22. North America Anti-Parkinson Drugs Market Share by Application (2016-2027)
Figure 23. North America Anti-Parkinson Drugs Market Share by Country (2016-2027)
Figure 24. United States Anti-Parkinson Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada Anti-Parkinson Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Anti-Parkinson Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Anti-Parkinson Drugs Market Share by Type (2016-2027)
Figure 28. Europe Anti-Parkinson Drugs Market Share by Application (2016-2027)
Figure 29. Europe Anti-Parkinson Drugs Market Share by Country (2016-2027)
Figure 30. Germany Anti-Parkinson Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France Anti-Parkinson Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. Anti-Parkinson Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy Anti-Parkinson Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia Anti-Parkinson Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic Anti-Parkinson Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Anti-Parkinson Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Anti-Parkinson Drugs Market Share by Type (2016-2027)
Figure 38. Asia-Pacific Anti-Parkinson Drugs Market Share by Application (2016-2027)
Figure 39. Asia-Pacific Anti-Parkinson Drugs Market Share by Region (2016-2027)
Figure 40. China Anti-Parkinson Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan Anti-Parkinson Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea Anti-Parkinson Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia Anti-Parkinson Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India Anti-Parkinson Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia Anti-Parkinson Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Anti-Parkinson Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Anti-Parkinson Drugs Market Share by Type (2016-2027)
Figure 48. Latin America Anti-Parkinson Drugs Market Share by Application (2016-2027)
Figure 49. Latin America Anti-Parkinson Drugs Market Share by Country (2016-2027)
Figure 50. Mexico Anti-Parkinson Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil Anti-Parkinson Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Anti-Parkinson Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Anti-Parkinson Drugs Market Share by Type (2016-2027)
Figure 54. Middle East & Africa Anti-Parkinson Drugs Market Share by Application (2016-2027)
Figure 55. Middle East & Africa Anti-Parkinson Drugs Market Share by Country (2016-2027)
Figure 56. Turkey Anti-Parkinson Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia Anti-Parkinson Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE Anti-Parkinson Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. AbbVie Revenue Growth Rate in Anti-Parkinson Drugs Business (2016-2021)
Figure 60. Mylan Laboratories Revenue Growth Rate in Anti-Parkinson Drugs Business (2016-2021)
Figure 61. Valeant Pharmaceuticals Revenue Growth Rate in Anti-Parkinson Drugs Business (2016-2021)
Figure 62. Novartis Revenue Growth Rate in Anti-Parkinson Drugs Business (2016-2021)
Figure 63. GlaxoSmithKline Revenue Growth Rate in Anti-Parkinson Drugs Business (2016-2021)
Figure 64. Zambon Pharmaceuticals Revenue Growth Rate in Anti-Parkinson Drugs Business (2016-2021)
Figure 65. Pfizer, Inc. Revenue Growth Rate in Anti-Parkinson Drugs Business (2016-2021)
Figure 66. Hoffmann-La Roche Revenue Growth Rate in Anti-Parkinson Drugs Business (2016-2021)
Figure 67. Merck & Co. Revenue Growth Rate in Anti-Parkinson Drugs Business (2016-2021)
Figure 68. Orion Pharma Revenue Growth Rate in Anti-Parkinson Drugs Business (2016-2021)
Figure 69. UCB Revenue Growth Rate in Anti-Parkinson Drugs Business (2016-2021)
Figure 70. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Anti-Parkinson Drugs Business (2016-2021)
Figure 71. Vertical Pharmaceuticals, LLC Revenue Growth Rate in Anti-Parkinson Drugs Business (2016-2021)
Figure 72. ACADIA Pharmaceuticals Inc. Revenue Growth Rate in Anti-Parkinson Drugs Business (2016-2021)
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed
世界のインスリン非依存型糖尿病治療薬市場規模・現状・予測（2021年-2027年） Diabetes is a metabolic disease, wherein the body is either unable to secret insulin (type 1 diabetes) or is unable to utilize the generated insulin (type 2 diabetes). Market Analysis and Insights: Global Non Insulin Anti diabetes Drugs Market The global Non Insulin Anti diabetes Drugs market size i…- 世界のパーキンソン病治療市場規模・現状・予測（2021年-2027年） Parkinson’s disease (PD) is a chronic and progressive disease, considered an idiopathic form, and accounts for roughly 80% of the cases of Parkinsonism—neurological disorders that lead to movement problems. While the exact cause of Parkinson’s disease is unknown, it may include a number of factors s…
- 世界の抗喘息薬＆COPD薬市場規模・現状・予測（2021年-2027年） The anti-asthmatics and chronic obstructive pulmonary disease (COPD) market consists of sales of anti-asthmatics and chronic obstructive pulmonary disease (COPD) drugs which are used to relieve the frequency of acute attacks of asthma, emphysema, chronic bronchitis, and nocturnal awakenings. The cla…
- 世界の非ステロイド性抗炎症薬（NSAID）市場規模・現状・予測（2021年-2027年） Nonsteroidal anti-inflammatory drugs (NSAIDs) are a drug class that reduce pain, decrease fever, prevent blood clots and, in higher doses, decrease inflammation. Side effects depend on the specific drug, but largely include an increased risk of gastrointestinal ulcers and bleeds, heart attack and ki…
- 世界のアンチエイジング薬＆デバイス市場規模・現状・予測（2021年-2027年） Aging is a natural phenomenon that is peculiar to all living things. However, accumulating findings indicate that senescence could be postponed or prevented by certain approaches. Substantial evidence has emerged supporting the possibility of radical human health and lifespan extension, in particula…